L-Leu-OBu | 2885-08-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-Leu-OBu
• 英文别名: L-leucine butyl ester；L-Leucin-butylester；butyl (2S)-2-amino-4-methylpentanoate
• CAS: 2885-08-7
• 化学式: C₁₀H₂₁NO₂
• 分子量: 187.282
• InChiKey: HYPLQEHLQMSBKE-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  L-Leu-OBu 、 (2R,3R)-3-Chlorocarbonyl-oxirane-2-carboxylic acid ethyl ester 在 三乙胺 作用下， 以 乙醚 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Relationship between Structure and Papain Inhibitory Activity of Epoxysuccinyl Amino Acid Derivatives

  摘要：

  一些DL-Zra/w-环氧琥珀酸氨基酸衍生物被新合成并用于木瓜蛋白酶抑制的结构-活性关系研究。通式为R1O-ES-AA-OR2（ES，DL-反式环氧琥珀酰基团；AA，氨基酸残基）。AA为支链烷基氨基酸，如Leu、He和Val，R1为氢或被苯基或环烷基取代的烷基，这类衍生物具有较好的活性。但R2或ES和AA的光学活性对活性的影响不大。

  DOI：

  10.1080/00021369.1981.10864575
• 作为产物：
  描述：

  正溴丁烷 、 L-亮氨酸 在 四丁基溴化铵 、 potassium carbonate 作用下， 以 水 、 苯 为溶剂， 反应 6.0h， 以65%的产率得到L-Leu-OBu
  参考文献：
  名称：

  Puntambekar, Hemalata M; Naik, D G; Kapadi, A H, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1993, vol. 32, # 7, p. 793 - 794

  摘要：

  DOI：

文献信息

• Method and compositions for identifying anti-HIV therapeutic compounds
  申请人：GILEAD SCIENCES, INC.

  公开号：US20040121316A1

  公开（公告）日：2004-06-24

  Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

  提供了一种鉴定含有羧酸酯或磷酸酯基团抗HIV治疗化合物的方法。可以选择使用新型酶GS-7340酯水解酶筛选这类化合物的文库。还提供了与GS-7340酯水解酶相关的组合物和方法。
• MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS
  申请人：Marsault Eric

  公开号：US20100093720A1

  公开（公告）日：2010-04-15

  The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.

  本发明提供了与胃动素受体及其亚型、异构体和/或变体结合和/或是功能调节剂的构象定义明确的大环化合物。这些大环化合物至少具有足够的药理特性，可用作治疗一系列疾病指示的治疗药物。特别是，这些化合物对于治疗和预防以高胃动素血症和/或胃肠道高蠕动性为特征的疾病非常有用，包括但不限于腹泻、癌症治疗相关腹泻、癌症诱导腹泻、化疗诱导腹泻、放射性肠炎、放射性腹泻、压力诱导腹泻、慢性腹泻、艾滋病相关腹泻、C. difficile相关腹泻、旅行者腹泻、移植物宿主病引起的腹泻、其他类型的腹泻、消化不良、肠易激综合征、化疗诱导的恶心和呕吐（呕吐）以及术后恶心和呕吐和功能性胃肠道疾病。此外，这些化合物对于治疗以胃或肠道吸收不良为特征的疾病和疾病也具有用途，例如短肠综合征、乳糜泻和虚弱。这些化合物还可用于治疗胃肠道炎症性疾病和疾病，如炎症性肠病、溃疡性结肠炎、克罗恩病和胰腺炎。因此，本发明还提供了治疗此类疾病的方法和包括本发明化合物的药物组合物。
• COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
  申请人：SURLERAUX Dominique

  公开号：US20120251487A1

  公开（公告）日：2012-10-04

  Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了用于治疗肝脏疾病，包括HCV感染的化合物、组合物和方法。在一个实施例中，披露了核苷类衍生物的化合物和组合物，这些化合物可以单独或与其他抗病毒药物联合使用。
• Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias
  作者：Kandukuri S. P. Bhushana Rao、Marie Paule M. Collard、Jean Paul C. Dejonghe、Ghanem Atassi、Jean A. Hannart、Andre Trouet

  DOI：10.1021/jm00146a017

  日期：1985.8

  esters to the vinblastin-23-oyl moiety through an amide linkage. Studies were extended to explore the influence of the nature of the amino acid, the ester alkyl chain lengths, the stereoisomerism of the amino acid, or the reacetylation of the hydroxyl group (position O-4) of the vindoline moiety. The present study deals with the synthesis of 21 vinblastin-23-oyl amino acid derivatives, some of their physicochemical

  二聚生物碱长春碱（VLB）和长春新碱（VCR）在结构上仅在二氢吲哚氮上的官能团上不同。半合成衍生物长春地辛（VDS）与VLB的区别在于其具有酰胺基而不是酯基。但是，这些微小的区别导致了这些化合物在溶瘤光谱，效价和毒性方面的巨大差异。Vinblastin-23-oyl氨基酸衍生物是通过酰胺键将氨基酸羧酸酯与Vinblastin-23-oyl部分相连而合成的。扩展了研究以探讨氨基酸的性质，酯烷基链长度，氨基酸的立体异构性或长春藤碱部分的羟基（位置O-4）的重新乙酰化的影响。
• Method and compositions for identifying anti-hiv therapeutic compounds
  申请人：Birkus Gabriel

  公开号：US20060115815A1

  公开（公告）日：2006-06-01

  Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

  提供了一种鉴定具有羧酸酯或膦酸酯基团的抗HIV治疗化合物的方法。可以使用新型酶GS-7340 Ester Hydrolase筛选这些化合物的库。还提供了与GS-7340 Ester Hydrolase相关的组合物和方法。